3--hydroxy-5--(4-isobutylpiperazinyl)benzoxazinorifamycin and HIV-Infections

3--hydroxy-5--(4-isobutylpiperazinyl)benzoxazinorifamycin has been researched along with HIV-Infections* in 1 studies

Other Studies

1 other study(ies) available for 3--hydroxy-5--(4-isobutylpiperazinyl)benzoxazinorifamycin and HIV-Infections

ArticleYear
Optimization of Benzoxazinorifamycins to Minimize hPXR Activation for the Treatment of Tuberculosis and HIV Coinfection.
    ACS infectious diseases, 2022, 08-12, Volume: 8, Issue:8

    Tuberculosis (TB) is one of the most significant world health problems, responsible for 1.5 M deaths in 2020, and yet, current treatments rely largely on 40 year old paradigms. Although the rifamycins (RIFs), best exemplified by the drug rifampin (RMP), represent a well-studied and therapeutically effective chemotype that targets the bacterial RNA polymerase (RNAP), these agents still suffer from serious drawbacks including the following: 3-9 month treatment times; cytochrome P450 (Cyp450) induction [particularly problematic for human immunodeficiency virus-

    Topics: Adult; HIV Infections; Humans; Pregnane X Receptor; Rifampin; Rifamycins; Tuberculosis

2022